A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Completed · Phase 3

Conditions studied: HIV Infections

In brief

To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (\< 400 copies/ml) at week 16 and 24 of study therapy. To determine the absolute change in plasma HIV-1 RNA and in absolute CD4 cell count during the 24 weeks of study treatment. To collect safety data on the treatment regimens. To determine the percentage of patients without SQV soft gel capsules resistance-associated mutations at week 24.

Key facts

Study ID

NCT00002178

Run by

Hoffmann-La Roche

People needed

375

Last updated by the study team

2005-06-24

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV RNA >= 5000 copies/ml by Amplicor assay.
• Signed, informed consent from parent or legal guardian for patients less than 18 years old.
• Previous treatment with antiretrovirals.

Where it is running

• Dr Charles Farthing — Los Angeles, California, United States
• Community Research Initiative — Brookline, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.